If youre curious about whether a dual-action medication could be suitable for your health goals, we invite you to complete our [free assessment quiz]
Myometry data from children five years of age and older indicated that upper extremity strength was greater in the placebo group (Supplemental Table S5, p.03), but lower extremity myometry data demonstrated no difference between groups
Outcome events of interest include time to: histological progression to cirrhosis, uncontrolled ascites, HCC, liver transplantation/transplant eligibility, and hospitalisation for hepatic decompensation or death.85 Key Point Currently OCA is being evaluated in a large phase III, randomised, placebo-controlled trial Elafibranor Elafibranor is another agent currently in phase III for the treatment of NASH
Each puncture is an opportunity for microbial entry
111 , QT (1050 M) was adequate to increase CYP11A1 promoter activity